NuVasive Receives a Hold from Cantor Fitzgerald

By Austin Angelo

In a report released yesterday, Craig Bijou from Cantor Fitzgerald maintained a Hold rating on NuVasive (NASDAQ: NUVA), with a price target of $58. The company’s shares closed yesterday at $58.05.

Bijou observed:

“: We maintain our Neutral rating on NUVA, but raise our PT to $58 from $54, as we see less downside risk to the stock than what we thought heading into 2Q. Although we are encouraged by the better-than-expected organic top-line growth in 2Q, we note that it is only one quarter. That said, NUVA’s 2H comps are significantly easier, particularly in the US, and suggest that NUVA could sustain organic growth at its 2Q level in 2H. NUVA’s guidance implies 2H organic growth of 6%+, a meaningful step up from 1H (+3%). Given the repeated delays in realizing GM improvement from the West Carrollton facility, we continue to see risk in NUVA’s ability to deliver on its 2018 operating margin guidance (OM).”

According to TipRanks.com, Bijou is a 5-star analyst with an average return of 26.7% and a 86.1% success rate. Bijou covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and Wright Medical Group.

Currently, the analyst consensus on NuVasive is a Hold with an average price target of $60.33.

See today’s analyst top recommended stocks >>

NuVasive’s market cap is currently $2.98B and has a P/E ratio of 73.48. The company has a Price to Book ratio of 3.90.

Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NUVA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NuVasive, Inc. engages in the development of minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. It offers cervical and spine fusion surgery, cervical plating, and posterior fixation products. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.